An individual in Ontario diagnosed with Stage 4 melanoma has encountered obstacles in accessing public funding for out-of-country drug treatments after seeking urgent therapy in the United States. Alex Shved, a 37-year-old father of two, took legal action against the Ontario Health Insurance Plan (OHIP) following rejections of his oncologist’s request for tumour-infiltrating lymphocyte therapy in Florida, which carries a cost of approximately US$600,000.
Although Shved won his case in court, he expressed disappointment as the government enacted changes to the law to uphold its actions that were deemed unlawful by the courts. OHIP’s refusal was based on the therapy’s pending review for public funding in Ontario, with concerns raised about potential disruptions to the drug review process.
A recent Divisional Court ruling found OHIP’s reasoning insufficient and mandated a reevaluation of Shved’s treatment request. Despite this, OHIP rejected his request for the third time, prompting Health Minister Sylvia Jones to announce regulatory amendments specifying that out-of-country drug funding will only be granted if the drug is already funded in the province but temporarily inaccessible.
Minister Jones emphasized the government’s commitment to safeguarding Ontario patients and taxpayers from exorbitant pricing while ensuring access to life-saving medications. In Shved’s case, discussions are ongoing to reach a satisfactory resolution, although specifics remain unclear to him. Shved, who has been exploring various treatments since his initial diagnosis in 2020, is considered a suitable candidate for TIL therapy, a process involving the extraction, multiplication, and reinfusion of immune cells to combat cancer.
While a variant of TIL therapy known as lifileucel received Health Canada approval for sale last year, it is currently undergoing assessments for potential provincial drug plan funding, a procedure that may span several years.
